. 2016 May 4;94(5):993–1001. doi: 10.4269/ajtmh.15-0665

Table 1.

Study details for “forced degradation” and “natural aging” of artemisinin-based combination therapies

Location of study	Formulation and manufacturer	Manufacture information
Forced degradation
60°C oven (LSHTM) Study date October 2013 to December 2013	Winthrop^® (100 mg AS/270 mg AQ) Sanofi-Aventis Group, Maphar Laboratories, Morocco	Lot 5491 Expiry: May 2015
	Coartem^® (20 mg AM/120 mg LUM) Novartis, China	Lot X1607 Expiry: September 2014
	Waipa (30 mg DHA/225 mg PIP) Kunimed Pharmachem Ltd., Nigeria	Lot SFH08 Expiry: December 2013
Natural aging
Ghana (KHRC) Study date January 2011 to January 2014	Winthrop^® (100 mg AS/270 mg AQ) Sanofi-Aventis Group, Maphar Laboratories, Morocco	Lot 5186 Expiry: June 2012
Ghana (KHRC) Study date January 2011 to January 2014	Coartem^® (20 mg AM/120 mg LUM) Novartis, China	Lot X1448 Expiry: December 2012
Stability chamber (LSHTM)	Winthrop^® (100 mg AS/270 mg AQ) Sanofi-Aventis Group, Maphar Laboratories, Morocco	Lot 5186 Expiry: June 2012
Stability chamber (LSHTM)	Coartem^® (20 mg AM/120 mg LUM) Novartis, China	Lot X1448 Expiry: December 2012

AM = artemether; AS = artesunate; AQ = amodiaquine; DHA = dihydroartemisinin; KHRC = Kintampo Health Research Center; LSHTM = London School of Hygiene and Tropical Medicine; LUM = lumefantrine; PIP = piperaquine.